What Did Big Pharma Earnings Say About China Growth?
This article was originally published in PharmAsia News
Executive Summary
Moving from a mixed to a more pessimistic outlook, top executives at multinational drug firms see China as fast losing its shine, despite the country continuing to lead growth in the emerging markets. PharmAsia News has combed through quarterly earnings reports to bring you the winners, laggards and most successful growth strategies in this increasingly challenging market.
You may also be interested in...
China Pediatric Slowdown Prompts Abbott Caution
Slowing growth in China, particularly in some consumer sectors, has prompted words of caution from Abbott over the outlook for the remainder of the year, although its CEO remains positive on this key emerging market.
Bounce Or More Bumps? New China Market Data Offer Bit Of Both
Two new sets of data on growth in China’s turbulent pharma sector paint a mixed and complex picture, indicating both challenges and opportunities ahead for multinational and domestic firms in the country.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.